Saturday 17 October 2026
Export BSX’s income statement to Excel — free account
Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 7.53%, EPS grew 14.8%, free cash flow grew 13.3% and total debt rose 8.95%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
44.39
0.25
+0.57%
Follow BSX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
12.52% | 12.47% | 14.69% | 15.37% | |
Piotroski F-Score |
6 | 7 | 8 | 7 | |
| 6.91% | 6.98% | 8.44% | 8.47% | ||
ROIC |
6.38% | 6.65% | 6.64% | 6.96% | |
Return on Tangible Assets |
42.94% | 39.21% | 43.60% | 64.81% | |
Average Days of Receivables |
53.34 | 53.20 | 53.60 | 53.01 | |
Free Cash Flow per Share |
2.58 | 2.47 | 2.34 | 2.47 | |
Free Cash Flow |
3,824.00 | 3,658.00 | 3,475.00 | 3,625.00 | |
Capital Expenditures |
(802.00) | (876.00) | (866.00) | (904.00) | |
| Other line items | |||||
Cash ROIC |
10.48% | 9.66% | 9.01% | 9.46% | |
Accounts Receivable Turnover |
7.26 | 7.32 | 7.21 | 7.16 | |
Accounts Payable Turnover |
6.37 | 5.91 | 5.93 | 5.76 | |
Inventory Turnover |
2.14 | 2.16 | 2.13 | 2.07 | |
Average Days of Payables |
60.16 | 67.12 | 65.50 | 71.15 | |
Days of Inventory on Hand |
175.38 | 172.67 | 178.94 | 186.98 | |
Tax Rate |
(0.15) | (0.15) | (0.05) | (0.05) | |
Research and Development Expense of Revenue |
10.04% | 10.22% | 10.31% | 10.25% | |
Selling, General and Administrative Expense of Revenue |
34.70% | 34.54% | 34.52% | 34.29% | |
Share Based Compensation of Revenue |
1.53% | 1.49% | 1.49% | 1.52% | |
Interest Coverage |
10.23 | 10.35 | 10.61 | 11.43 | |
Operating CF/Net income |
1.66 | 1.56 | 1.22 | 1.23 | |
Depreciation/Fixed assets |
0.40 | 0.35 | 0.35 | 0.34 | |
Capex/Depreciation |
(0.53) | (0.62) | (0.60) | (0.64) | |
Revenue per Share |
13.06 | 13.56 | 13.88 | 14.28 | |
Operating CF per Share |
3.12 | 3.06 | 2.92 | 3.08 | |
Capex per Share |
(0.54) | (0.59) | (0.58) | (0.61) | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.04 |
Columns are period end dates